MR

Millie Ray

Life Sciences Company Creation

United States

Investor
VC

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Genomics
Epigenetics
RNAseq
ChIP-seq
Stem Cells
Chromatin
Transcriptional Regulation
Transcriptomics
Cell
Biotechnology
Biochemistry
Protein Purification
CRISPR
Protein Chemistry
Laboratory
Microarray
Fluorescence Microscopy
Genetics
Statistics
Science

Education

Investments

Casma Therapeutics

Series B

Total Funding: $160M

Hexagon Bio

Series A

Total Funding: $190M

Work Experience

The Column Group

2017

  • Partner

    2022

  • Principal

    2019 - 2022

  • Associate

    2017 - 2018

Foghorn Therapeutics

2016 - 2017

  • Business Associate

    2016 - 2017

Flagship Ventures - Venture Labs

2015 - 2016

  • Fellow and Associate

    2015 - 2016

Massachusetts General Hospital

2008 - 2015

  • Graduate Student and Post- Doctoral Researcher- Kingston Lab

    2008 - 2015

Broad Institute

2014 - 2015

  • Ebola Genomics team - Sabeti Lab

    2014 - 2015

    Implemented first Next Generation Sequencer to run in West Africa for high capacity Ebola surveillance and diagnostics tools.